Start Your Search
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
P3.01-73 - Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion. (ID 12026)
12:00 - 13:30 | Author(s): Miyuki Nagaoka
Globally, talc pleurodesis is the standard treatment for malignant pleural effusion. In Japan, a combination of minocycline (MINO) and OK-432 has been commonly used for treating pleurodesis of malignant pleural effusion; however, data comparing talc and MINO + OK-432 are insuffient.
To compare the success rates and adverse events of talc and MINO + OK-432.
We retrospectively assessed 73 patients receiving pleurodesis for malignant pleural effusion (lung cancer, 60; malignant mesothelioma, 3; others, 10) for the first time between January 2010 and January 2017 at our hospital. We assessed the rates of fever, pain, after drug administration and success of pleurodesis. Moreover, we assessed the difference in success rates according to the pathology of the disease or chemotherapy.4c3880bb027f159e801041b1021e88e8 Result
Of the 73 patients, 51 were men and 22 were women, the median age was 75 years (range 47-98). The rate of fever was significantly low in the talc group, although no statistical difference was observed in the success rate (talc, 75.9%, MINO + OK-432, 85.1%), period of drainage tube insertion (3.2 and 3.6 days) and the rate of pain (30% and 50%). No statistical difference according to the pathology of the disease or chemotherapy was observed.8eea62084ca7e541d918e823422bd82e Conclusion
Thus, we can perform pleurodesis in patients with talc less invasively than with MINO + OK-432.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.